2. Search Result
Search Result
Results for "

Liver fibrosis

" in MedChemExpress (MCE) Product Catalog:

198

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dyes

9

Biochemical Assay Reagents

20

Peptides

1

MCE Kits

1

Inhibitory Antibodies

33

Natural
Products

4

Isotope-Labeled Compounds

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129389
    Benzyl-α-GalNAc
    5+ Cited Publications

    		 Glycosyltransferase Cancer
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .
    Benzyl-α-GalNAc
  • HY-Y0698
    Thioacetamide
    4 Publications Verification

    Acetothioamide; TAA; Thiacetamide

    		 Necroptosis Neurological Disease Inflammation/Immunology Cancer
    Thioacetamide (TAA) is an indirect hepatotoxin and causes parenchymal cell necrosis. Thioacetamide requires metabolic activation by microsomal CYP2E1 to thioacetamide-S-oxide initially and then to thioacetamide-S-dioxide, which is a highly reactive metabolite, and its reactive metabolites covalently bind to proteins and lipids thereby causing oxidative stress and centrilobular necrosis. Thioacetamide can induce chronic liver fibrosis, encephalopathy and other events model .
    Thioacetamide
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    		 HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-W008947
    SEW​2871
    5+ Cited Publications

    		 LPL Receptor ERK Akt Neurological Disease Metabolic Disease Inflammation/Immunology
    SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .
    SEW​2871
  • HY-W037893
    CHMA1004 dihydrochloride
    2 Publications Verification

    Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1

    		 METTL3 HIV Infection Neurological Disease
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m 6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection .
    CHMA1004 dihydrochloride
  • HY-124748A
    ENMD-1068 hydrochloride
    2 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Inflammation/Immunology
    ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis .
    ENMD-1068 hydrochloride
  • HY-P1136B
    TAT-Gap19
    1 Publications Verification

    		 Gap Junction Protein Cardiovascular Disease Inflammation/Immunology
    TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice .
    TAT-Gap19
  • HY-N1548
    Prunasin
    1 Publications Verification

    		 DNA/RNA Synthesis Inflammation/Immunology
    Prunasin is an orally active cyanogenic glucoside and the main metabolite of Amygdalin (HY-N0190). Prunasin can specifically inhibit rat DNA polymerase β (IC50: 98 μM). Prunasin has anti-inflammatory and anti-fibrotic activities. Prunasin can be used in the research of diseases such as liver fibrosis .
    Prunasin
  • HY-101473
    EMD527040
    1 Publications Verification

    		 Integrin Inflammation/Immunology
    EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research .
    EMD527040
  • HY-151427
    TGFβ1-IN-1
    3 Publications Verification

    		 TGF-β Receptor Inflammation/Immunology
    TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies .
    TGFβ1-IN-1
  • HY-147041
    Selvigaltin
    1 Publications Verification

    GB1211

    		 Galectin Inflammation/Immunology Cancer
    Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis .
    Selvigaltin
  • HY-137978A
    Ezurpimtrostat hydrochloride
    3 Publications Verification

    GNS561 hydrochloride

    		 SARS-CoV IFNAR Autophagy Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
    Ezurpimtrostat hydrochloride
  • HY-N0546
    Ligustroflavone
    2 Publications Verification

    Nuezhenoside

    		 CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .
    Ligustroflavone
  • HY-10327
    GW-6604

    		TGF-β Receptor Metabolic Disease
    GW-6604 is an ALK5 inhibitor with an IC50 value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis .
    GW-6604
  • HY-47888
    PLN-1474

    		Integrin Inflammation/Immunology
    PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.
    PLN-1474
  • HY-P991219
    Anti-IL11RA Antibody (X209)

    EnX209

    		 Interleukin Related ERK MMP Inflammation/Immunology
    Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Anti-IL11RA Antibody (X209)
  • HY-N0912
    Rehmannioside D
    1 Publications Verification

    		 Sirtuin Apoptosis MDM-2/p53 Reactive Oxygen Species (ROS) Bcl-2 Family Caspase Metabolic Disease Inflammation/Immunology
    Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
    Rehmannioside D
  • HY-P1636
    Hirudin (54-65)

    		Thrombin YAP Calcium Channel Metabolic Disease
    Hirudin (54-65) is a thrombin antagonist and YAP suppressor with anticoagulatory properties.Hirudin (54-65) blocks thrombin's anion binding site, acts on soluble and thrombus-bound thrombin.Hirudin (54-65) suppresses thrombin-induced profibrotic YAP activity, reduces YAP expression, nuclear translocation, and downstream effector signaling in vascular endothelial cells.Hirudin (54-65) ameliorates obstructive cholestasis, attenuates liver fibrosis symptoms, fibrosis-associated angiogenesis, and endothelial-to-mesenchymal transition.Hirudin (54-65) reduces liver inflammation and tissue hypoxia.Hirudin (54-65) promotes extracellular calcium influx through L-type calcium channels in canine coronary artery smooth muscle, mediates contraction.Hirudin (54-65) induces endothelium-independent contraction of canine coronary arterial segments; this response is not affected by indomethacin pretreatment.Hirudin (54-65) can be used for the research of liver obstructive cholestasis, liver fibrosis .
    Hirudin (54-65)
  • HY-135644
    Rencofilstat
    1 Publications Verification

    CRV431

    		 Cyclophilin Sirtuin Nuclear Factor of activated T Cells (NFAT) Interleukin Related Cancer
    Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
    Rencofilstat
  • HY-100775A
    Fezagepras
    1 Publications Verification

    Setogepram; PBI-4050

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
    Fezagepras
  • HY-132850
    Dazcapistat

    BLD-2660

    		 Proteasome Interleukin Related Infection Inflammation/Immunology
    Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis .
    Dazcapistat
  • HY-151932
    FXR agonist 3
    1 Publications Verification

    		 FXR Inflammation/Immunology
    FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .
    FXR agonist 3
  • HY-168906
    BI-113823

    		Bradykinin Receptor PI3K Akt TNF Receptor ERK Neurological Disease Inflammation/Immunology
    BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension .
    BI-113823
  • HY-100775
    Fezagepras sodium
    1 Publications Verification

    Setogepram sodium; PBI-4050 sodium

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
    Fezagepras sodium
  • HY-170538
    SNT-5382

    		Lysyl Oxidase Cytochrome P450 Cardiovascular Disease Metabolic Disease
    SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis .
    SNT-5382
  • HY-P5345
    KLA peptide

    		Apoptosis Antibiotic Caspase Mitochondrial Metabolism Cardiovascular Disease Infection Neurological Disease Metabolic Disease
    KLA peptide is a naturally occurring Antibiotic peptide that is nontoxic outside of cells but is toxic when it enters into the interior of targeted cells. KLA peptide can induce cell Apoptosis by disrupting mitochondrial membranes and activating Caspase. MG1-KLA, formed by the coupling of KLA peptide with MG1, can selectively induce apoptosis in pro-inflammatory microglia. KLA peptide can be used for the research of liver fibrosis. KLA peptide can be used for the research of neonatal hypoxic-ischemic encephalopathy.
    KLA peptide
  • HY-B1588
    Carbenoxolone
    5+ Cited Publications

    		 Amyloid-β Gap Junction Protein Neurological Disease Metabolic Disease
    Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis .
    Carbenoxolone
  • HY-177810
    IGFIIR aptamer sodium

    		Insulin Receptor Cancer
    IGFIIR aptamer sodium is an IGFIIR-specific aptamer that can be potentially used as a targeting ligand for the treatment and diagnosis of liver fibrosis.
    IGFIIR aptamer sodium
  • HY-156065
    S217879

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related Metabolic Disease
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
    S217879
  • HY-169004
    CBT-295

    		TGF-beta/Smad Interleukin Related Neurological Disease Inflammation/Immunology
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .
    CBT-295
  • HY-113806
    (±)-Trolline

    (±)-Oleracein E

    		 Bacterial Influenza Virus Apoptosis Infection Inflammation/Immunology
    (±)-Trolline ((±)-Oleracein E), an isoquinoline alkaloid, exhibits antibacterial activity against respiratory bacteria and antiviral activity against influenza virus A and B. (±)-Trolline significantly induces HSC apoptosis. (±)-Trolline can be used for the research of liver fibrosis .
    (±)-Trolline
  • HY-P1136C
    TAT-Gap19 TFA
    1 Publications Verification

    		 Gap Junction Protein Cardiovascular Disease Inflammation/Immunology
    TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice .
    TAT-Gap19 TFA
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50 : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-12530R
    Velpatasvir (Standard)

    GS-5816 (Standard)

    		 Reference Standards HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir (Standard)
  • HY-173235
    Galectin-3-IN-6

    		Galectin Cardiovascular Disease Inflammation/Immunology Cancer
    Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis .
    Galectin-3-IN-6
  • HY-179133
    HDB-1

    		P2Y Receptor PKA Raf MEK ERK Inflammation/Immunology
    HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .
    HDB-1
  • HY-P11348
    TG-MMP-Lys

    		MMP Cancer
    TG-MMP-Lys is an MMP-sensitive crosslinking peptide. TG-MMP-Lys is promising for research of fibrotic diseases (e.g., liver fibrosis) .
    TG-MMP-Lys
  • HY-155786
    3,7-DMF

    		TGF-beta/Smad Others
    3,7-DMF is an orally active inhibitor of TGF-β1-induced activation of HSCs. 3,7-DMF induces antioxidant genes and quenches ROS away, which can be used to study liver fibrosis .
    3,7-DMF
  • HY-134221
    S-Nitroso-N-acetylcysteine

    		Adrenergic Receptor Reactive Oxygen Species (ROS) Cardiovascular Disease
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .
    S-Nitroso-N-acetylcysteine
  • HY-127166
    Colchiceine

    O10-Demethylcolchicine

    		 Microtubule/Tubulin Inflammation/Immunology
    Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis .
    Colchiceine
  • HY-141411
    (Rac)-Zevaquenabant

    (Rac)-MRI-1867

    		 Cannabinoid Receptor NO Synthase Others
    (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis .
    (Rac)-Zevaquenabant
  • HY-156034A
    JT001 sodium

    NLRP3-IN-19 sodium

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
    JT001 sodium
  • HY-156034
    JT001

    NLRP3-IN-19

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
    JT001
  • HY-153114
    HEC96719

    		FXR Inflammation/Immunology
    HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
    HEC96719
  • HY-124748
    ENMD-1068

    		Protease Activated Receptor (PAR) Apoptosis Inflammation/Immunology
    ENMD-1068 is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 can be used in the study of endometriosis and liver fibrosis .
    ENMD-1068
  • HY-W008947R
    SEW​2871 (Standard)

    		Reference Standards LPL Receptor ERK Akt Neurological Disease Metabolic Disease Inflammation/Immunology
    SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .
    SEW​2871 (Standard)
  • HY-N16478
    Echihumiline

    		Cytochrome P450 Metabolic Disease
    Echihumiline is an alkaloid targeting hepatic cytochrome P450 enzymes (CYP450). Echihumiline induces DNA cross-linking and oxidative stress in hepatocytes, leading to liver necrosis and fibrosis. Echihumiline is promising for research of liver diseases .
    Echihumiline
  • HY-16521
    VX-166

    		Caspase Inflammation/Immunology
    VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .
    VX-166
  • HY-177608
    Rat IL10 mRNA

    		Interleukin Related Inflammation/Immunology
    Rat IL-10 mRNA encodes interleukin-10 (IL-10). IL-10 is expressed in tissues/cells such as hepatic stellate cells and is involved in physiological processes including liver fibrosis.
    Rat IL10 mRNA
  • HY-N0546R
    Ligustroflavone (Standard)

    Nuezhenoside (Standard)

    		 Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .
    Ligustroflavone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: